Determinants and outcome of amiodarone-associated thyroid dysfunction

Clinical Endocrinology

Volumn 75, Issue 3, 2011, Pages 388-394

  Ahmed, Sheba ^a   Van Gelder, Isabelle C ^a,b   Wiesfeld, Ans C P ^a   Van Veldhuisen, Dirk J ^a   Links, Thera P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; THYROTROPIN;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THYROID DISEASE; THYROID FUNCTION TEST; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTHYROIDISM; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; THYROID FUNCTION TESTS; THYROID GLAND; THYROTOXICOSIS; THYROTROPIN; TREATMENT OUTCOME;

EID: 79961225162     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04087.x     Document Type: Article

References (33)

1. Roy, D., Talajic, M., Dorian, P., et al. (2000) Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. New England Journal of Medicine, 342, 913-920. (Pubitemid 30177051)
2. Singh, B.N., Singh, S.N., Reda, D.J., et al. (2005) Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine, 352, 1861-1872.
3. Julian, D.G., Camm, A.J., Frangin, G., et al. (1997) Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet, 349, 667-674. (Pubitemid 27107744)
4. Cairns, J.A., Connolly, S.J., Roberts, R., et al. (1997) Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet, 349, 675-682. (Pubitemid 27107745)
5. Bardy, G.H., Lee, K.L., Mark, D.B., et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New England Journal of Medicine, 352, 225-237. (Pubitemid 40110811)
6. Zimetbaum, P., (2007) Amiodarone for atrial fibrillation. New England Journal of Medicine, 356, 935-941.
7. Ahmed, S., Rienstra, M., Crijns, H.J., et al. (2008) Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA, 300, 1784-1792.
8. Yiu, K.H., Jim, M.H., Siu, C.W., et al. (2009) Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. Journal of Clinical Endocrinology and Metabolism, 94, 109-114.
9. Klein, I., &, Ojamaa, K., (2001) Thyroid hormone and the cardiovascular system. New England Journal of Medicine, 344, 501-509. (Pubitemid 32164903)
10. Kahaly, G.J., &, Dillmann, W.H., (2005) Thyroid hormone action in the heart. Endocrine Reviews, 26, 704-728. (Pubitemid 41127279)
11. Biondi, B., Palmieri, E.A., Lombardi, G., et al. (2002) Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 87, 968-974. (Pubitemid 36121048)
12. Toft, A.D., &, Boon, N.A., (2000) Thyroid disease and the heart. Heart, 84, 455-460.
13. Bouvy, M.L., Heerdink, E.R., Hoes, A.W., et al. (2002) Amiodarone-induced thyroid dysfunction associated with cumulative dose. Pharmacoepidemiology and Drug Safety, 11, 601-606. (Pubitemid 35345412)
14. Rouleau, F., Baudusseau, O., Dupuis, J.M., et al. (2001) [Incidence and timing of thyroid dysfunction with long-term amiodarone therapy]. Archives des Maladies du Coeur et des Vaisseaux, 94, 39-43. (Pubitemid 32147144)
15. Martino, E., Safran, M., ghini-Lombardi, F., et al. (1984) Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Annals of Internal Medicine, 101, 28-34. (Pubitemid 14088063)
16. Trip, M.D., Wiersinga, W., &, Plomp, T.A., (1991) Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. American Journal of Medicine, 91, 507-511.
17. Tanda, M.L., Piantanida, E., Lai, A., et al. (2008) Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clinical Endocrinology, 69, 812-818.
18. Bartalena, L., Wiersinga, W.M., Tanda, M.L., et al. (2004) Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol (Oxf), 61, 494-502. (Pubitemid 39388489)
19. Martino, E., Bartalena, L., Bogazzi, F., et al. (2001) The effects of amiodarone on the thyroid. Endocrine Reviews, 22, 240-254. (Pubitemid 32458161)
20. Eskes, S.A., &, Wiersinga, W.M., (2009) Amiodarone and thyroid. Best Practice & Research. Clinical Endocrinology & Metabolism, 23, 735-751.
21. Osman, F., Franklyn, J.A., Sheppard, M.C., et al. (2002) Successful treatment of amiodarone-induced thyrotoxicosis. Circulation, 105, 1275-1277. (Pubitemid 34260414)
22. Uzan, L., Guignat, L., Meune, C., et al. (2006) Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. Drug Safety, 29, 231-236. (Pubitemid 43363835)
23. Baskin, H.J., (2006) American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. AACE Thyroid Task Force. Ref Type: Internet Communication.
24. Serdiuk, S.E., Bakalov, S.A., Golitsyn, S.P., et al. (2005) [Incidence and predictors of thyroid dysfunction caused by long-term intake of amiodaron]. Terapevticheskii Arkhiv, 77, 33-39. (Pubitemid 41695785)
25. Borowski, G.D., Garofano, C.D., Rose, L.I., et al. (1985) Effect of long-term amiodarone therapy on thyroid hormone levels and thyroid function. American Journal of Medicine, 78, 443-450. (Pubitemid 15107926)
26. Thorne, S.A., Barnes, I., Cullinan, P., et al. (1999) Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation, 100, 149-154. (Pubitemid 29330013)
27. Vanderpump, M.P., Tunbridge, W.M., French, J.M., et al. (1995) The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf), 43, 55-68.
28. Cohen-Lehman, J., Dahl, P., Danzi, S., et al. (2010) Effects of amiodarone therapy on thyroid function. Nature Reviews. Endocrinology, 6, 34-41.
29. Ursella, S., Testa, A., Mazzone, M., et al. (2006) Amiodarone-induced thyroid dysfunction in clinical practice. European Review for Medical and Pharmacological Sciences, 10, 269-278. (Pubitemid 44932339)
30. Eaton, S.E., Euinton, H.A., Newman, C.M., et al. (2002) Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf), 56, 33-38. (Pubitemid 34107319)
31. Loy, M., Perra, E., Melis, A., et al. (2007) Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiologica, 48, 628-634. (Pubitemid 47147755)
32. Macedo, T.A., Chammas, M.C., Jorge, P.T., et al. (2007) Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography. Acta Radiologica, 48, 412-421. (Pubitemid 46633873)
33. Bogazzi, F., Bartalena, L., &, Martino, E., (2010) Approach to the patient with amiodarone-induced thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 95, 2529-2535.